** Medical device maker Solventum's SOLV.N shares rise ~2.6% to $77.82
** Argus Research upgrades Solventum to "buy" from "hold"
** Brokerage says SOLV transformed into faster-growing and higher-margin business model
** Argus raises SOLV's 2026 adjusted EPS estimate to $5.98 from $5.95
** Four of 13 brokerages rate stock "buy" or higher, eight "hold" and one "sell"; their median PT is $85 - LSEG data
** Including session's moves, stock up ~17.3% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。